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Abstract
Background: A concentrate for bicarbonate haemodialysis acidified with citrate instead of acetate
has been marketed in recent years. The small amount of citrate used (one-fifth of the concentration
adopted in regional anticoagulation) protects against intradialyser clotting while minimally affecting
the calcium concentration. The aim of this study was to compare the impact of citrate- and acetate-
based dialysates on systemic haemodynamics, coagulation, acid-base status, calcium balance and
dialysis efficiency.
Methods: In 25 patients who underwent a total of 375 dialysis sessions, an acetate dialysate (A)
was compared with a citrate dialysate with (C+) or without (C) calcium supplementation (0.25
mmol/L) in a randomised single-blind cross-over study. Systemic haemodynamics were evaluated
using pulse-wave analysis. Coagulation, acid-base status, calcium balance and dialysis efficiency were
assessed using standard biochemical markers.
Results: Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP)
(-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm-5, p < 0.001) while stroke
volume was not increased. In hypertensive patients there was a substantial reduction in BP (-7.8
mmHg, p < 0.01). With the C+ dialysate the BP gap was less pronounced but the reduction in PR
was even greater (-226 dyne.sec.cm-5, p < 0.001). Analyses of the fluctuations in PR and of
subjective tolerance suggested improved haemodynamic stability with the citrate dialysate.
Furthermore, an increase in pre-dialysis bicarbonate and a decrease in pre-dialysis BUN, post-
dialysis phosphate and ionised calcium were noted. Systemic coagulation activation was not
influenced by citrate.
Conclusion: The positive impact on dialysis efficiency, acid-base status and haemodynamics, as
well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute
to improving haemodialysis in selected patients.
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A concentrate acidified with citric acid instead of the less
physiologic acetic acid has been successfully implemented
in the United States for bicarbonate haemodialysis over
the past 7 years [1-3]. In contrast to traditional regional
citrate anticoagulation, the small amount of citrate used
in the acid concentrate (0.8 mmol/L; only about one-fifth
of the concentration necessary to achieve anticoagulation
[1,4,5]) affects the calcium concentration and the locally
enhanced coagulation activation in a limited way, result-
ing in approximately 10% reduction in post-dialysis ion-
ized calcium and in no measurable systemic
anticoagulation [1]. The absence of significant systemic
repercussions is related not only to the low amount of cit-
rate used but also to the rapid conversion of citrate into
bicarbonate, which takes place in the liver and muscles
and results in a higher post-dialysis bicarbonataemia
[1,6,7]. Despite the rapid clearance of citrate, the local
consequences of removing calcium from the blood clot-
ting cascade have measurable positive effects on the dia-
lyser life-span in the "reuse" modality and on dialysis
quality, as quantified by urea Kt/V [1,3]. The improve-
ment in urea clearance has been correlated with an
assumed favourable effect on dialyser fibre permeability
mediated by the intradialyser anticoagulant properties of
citrate [1,3,8]. Considering the importance of limiting the
biocompatibility-related coagulation activation taking
place in the extracorporeal circuit [9-17], the availability
of a simple way to inhibit it without affecting systemic
coagulation and bleeding risk [18] is very promising.
Although thousands of patients have been treated in
recent years with haemodialysis fluids based on citric
instead of acetic acid, the haemodynamic tolerance (the
reduction in ionized calcium concentration and the
increase in bicarbonateamia could both result in a lower
intra-dialytic blood pressure [19-25]) and the amount of
systemic coagulation activation related to each one of the
modalities, have not been investigated.
The aim of this randomised, controlled, single-blind,
cross-over study in single-use dialyser bicarbonate haemo-
dialysis was to detail the consequences on systemic
haemodynamics (primary outcome) and on coagulation
activation, acid-base status, calcium balance and dialysis
efficiency (secondary outcomes) of using citric instead of
acetic acid in haemodialysis fluids.
Methods
Twenty-five chronic haemodialysis patients (15 male and
10 female) (sample size arbitrarily set in the absence of
previous data or studies with an analogous primary out-
come), undergoing dialysis in the dialysis unit of the
Ospedale la Carità (Locarno, Switzerland) 3 to 4 hours
three times a week who were clinically stable and without
intercurrent illnesses were enrolled in the study. A single-
blind, cross-over design was used in which the patients
were initially randomised (one to one beginning with ace-
tic acid dialysate according to the enrollement sequence)
into one of two arms of the study i.e. receiving either ace-
tic acid (modality A) or citric acid (modality C) dialysate.
In the following 3 weeks the modality was switched
weekly to the alternative one. Finally, with the intention
to compensate for the reduction in serum calcium
induced by citrate binding, both study arms were com-
pleted by a week in which patients were administered a
citric acid dialysate containing a calcium supplement of
0.25 mmol calcium/L (modality C+) (see Figure 1 for
details).
The haemodialyses were performed using a 4008 H
machine equipped with a cartridge of bicarbonate Bibag©
and a high-flux single-use modified polysulfone mem-
brane (Helixone©; FX 80 or 100 with an effective surface
area of 1.8 and 2.2 m2 and an ultrafiltration coefficient of
59 and 73 ml/h mmHg, respectively), all from Fresenius
Medical Care (Bad Homburg, Germany). Dialysis fluids
were produced by Bichsel AG (Interlaken, Switzerland);
the fluid composition was as following: sodium 138
mmol/L, magnesium 0.5 mmol/L, glucose 5.5 mmol/L,
potassium 2 mmol/L (individually adapted according to
the pre-dialysis serum potassium), acetate 3.0 mmol/L in
A and 0.3 in C and C+, citrate 0 mmol/L in A and 0.8 in C
and C+ and calcium 1.25 and 1.50 mmol/L in A and C
and 1.50 and 1.75 in C+. Intradialytic heparin anticoagu-
lation was carried out according to standard procedures
and continued without dose adaptations in both arms of
the study; priming of the dialyser was heparin free. The
prescribed dialyser effective surface area, dialysis fluid
conductibility, temperature and composition (with the
exception of acetate, citrate and calcium), and effective
blood flow were recorded at enrolment in the study and
were left unchanged for the following 5 weeks. The medi-
cations of the patients (including phosphate binders)
were also left unchanged.
Serum BUN, creatinine, potassium, phosphate, calcium
and whole-blood pH, bicarbonate and ionised calcium
were measured at the beginning and at the end of the third
dialysis session of each week. Ionised and total calcium
were also measured at the beginning and at the end of the
first dialysis session of each week. Prothrombin fragments
1+2 (F1+2) and thrombin-antithrombin complexes (TAT)
were determined at the beginning and at the end of the
third dialysis session of each week [26]. Blood samples
were taken from the arterial limb of the shunt.
Systolic and diastolic blood pressures and heart rate were
measured before the start of each session and then
repeated at 30-min intervals throughout dialysis with anPage 2 of 11
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ical Care, Bad Homburg, Germany) integrated in the dial-
ysis machine. Stroke volumes (integrated mean of the
flow waveform between the current upstroke and the
dicrotic notch) and peripheral resistances (ratio of mean
arterial pressure to stroke volume multiplied by heart
rate) were evaluated between 5 and 10 minutes after the
start of the session and then every 45 minutes using a fin-
ger beat-to-beat monitor Finometer© (Finapres Medical
Systems BV, Arnhem, The Netherlands). The use of isot-
onic saline infusions (100–200 ml) to treat symptomatic
hypotension or symptoms related to intravascular hypo-
volaemia was registered.
Kt/V was calculated using a second-generation single-pool
Daugirdas formula (Kt/V = -ln(R-0.03) + [(4-3.5 × R) ×
(UF/W)] where R = post-dialysis BUN/pre-dialysis BUN,
UF = net ultrafiltration and W = weight).
Citrate accumulation during dialysis was estimated by cal-
culating the calcium gap = |post – predialysis total cal-
cium| - |post – predialysis ionised calcium|[6]. In a post-
hoc analysis, 0.2 mmol/L was used as a cut-off value to
classify patients as rapid (< 0.2 mmol/L) or slow (= 0.2
mmol/L) metabolisers.
Results were expressed as mean ± SD. Statistical analyses
were performed using a statistical software package (SPSS
12.0; SPSS Inc., Chicago, IL, USA). Laboratory and
haemodynamic parameters were compared first with an
ANOVA and then, if significant, by a paired t-test of the
mean of the values obtained in each patient with each
modality. Haemodynamic parameters as a function of
dialysis time were compared using a trapezoidal estima-
tion of the area under the curves followed by a Wilcoxon
signed rank test. To better understand the haemodynamic
changes, an evaluation of the maximum increase and
decrease in each parameter was added to the data analysis
(see Figure 2 for an explanation of the calculation). Per-
centages were compared using Fisher's exact test. In all
cases, p = 0.05 was considered statistically significant; p
was expressed as ns (not significant), = 0.05, < 0.05, < 0.01
and < 0.001.
The protocol of the study was approved by the local Ethi-
cal Committee. All patients gave written informed consent
prior to enrolment in the study.
Results
Characteristics of the studied population
The characteristics of the studied population (n = 25) at
the time of enrollment were as follows (mean ± SD): age
Study designFigure 1
Study design. Schematic representation of the study design.Page 3 of 11
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ratio 1.5. The baseline haemodialysis prescriptions were:
dialyser effective surface area 1.86 ± 0.15 m2; dialysis
duration 3.54 ± 0.43 h; dialysis fluid conductibility 13.8
ms/cm; dialysis fluid temperature 36.5°C; effective blood
flow 305.64 ± 58.90 ml/min; dialysis fluid flow rate 536
± 99.50 ml/min and dialysis fluid concentration for potas-
sium 3.00 ± 0.75 mmol/L, magnesium 0.5 mmol/L, glu-
cose 5.5 mmol/L and acetate 3 mmol/L. See Table 1 for
details including underlying nephropathies, comorbidi-
ties and antihypertensive drugs in use. All participants
completed the 5 phases of the protocol (Figure 1). The
study was started on March 2007 and ended on Novem-
ber of the same year.
Haemodynamic consequences of dialysis fluids containing 
citrate instead of acetate
Mean systolic and diastolic blood pressures and mean
peripheral resistances in patients dialysed with citrate dia-
lysate were significantly lower than in patients dialysed
with acetate (-4.3 and -1.6 mmHg and -51 dyne.sec.cm-5;
p < 0.01 and p < 0.001 respectively). The associated slight
increase in stroke volume (+5.0 ml) was not significant.
Dialysate supplemented with 0.25 mmol calcium/L to
compensate for binding to citrate (see the following para-
graph for details) reduced the blood pressure gap between
the two dialysis schedules to a nonsignificant value (-2.0
and 0.8 mmHg respectively) whereas the gap in periph-
eral resistances increased further (-226 dyne.sec.cm-5; p <
0.001) (see Table 2 for details). Blood pressure, heart rate,
blood volume, peripheral resistances and stroke volume
as a function of haemodialysis time are depicted in Fig-
ures 3, 4, 5, 6, 7, 8.
This observation was confirmed in an analysis of the max-
imum fluctuations in systolic blood pressure during dial-
ysis, in which the citrate dialysate produced, respectively,
a larger decrease and a less pronounced increase (+6.4 and
-4.9 mmHg; p < 0.01 and p < 0.05 respectively).
Surprisingly, the opposite was observed regarding periph-
eral resistances with a less pronounced decrease (-489
dyne.sec.cm-5; p < 0.001) and a similar maximum increase
that was confirmed with citrate dialysate supplemented
with 0.25 mmol calcium/L (see Table 3 for details).
In analysing post-hoc the subgroup of patients with an
intradialytic systolic blood pressure increase of more than
15 mmHg and at least one value of more than 150 mmHg
(n = 8), we found that pressure values in citrate patients
were even lower (-7.8 mmHg; P < 0.05) (see Figure 9 for
details).
Acid-base status and electrolyte changes
The use of citrate dialysate resulted in a significant
increase in steady state pre-dialysis bicarbonate levels and
a decrease in post-dialysis phosphate levels (+0.95 and -
0.13 mmol/L; p < 0.01 and p < 0.001 respectively). The
potassium balance was not influenced significantly (see
Table 4 for details).
Unlike the absence of changes in the pre-dialysis ionised
calcium levels, those measured post-dialysis were signifi-
cantly lower in patients receiving citrate dialysate (- 0.08
mmol/L; p < 0.001). In the subgroup of patients treated
with 1.25 mmol calcium/L in the dialysis fluid (n = 6), an
asymptomatic post-dialysis hypocalcaemia was detected
(0.99 vs. 1.09 mmol/L post-dialysis ionised calcium/L; p <
0.01). Supplementing the citrate dialysate with 0.25
mmol calium/L (C+) completely corrected the difference
in post-dialysis ionised calcium previously observed
between the two dialysis schedules (see Table 5 for
details).
The value determined for the calcium gap defined as
(post-predialysis Δ total calcium) – (post-predialysis Δ
ionized calcium), was proportional to unmetabolised cit-
rate accumulation and allowed us to classify patients as
rapid or slow metabolisers (post-hoc analysis). In the
slow-metabolizer subgroup (n = 9), there were signifi-
cantly more patients with a net ultrafiltration during dial-
ysis that was > 2L (64 vs. 8%; p < 0.05); a similar trend,
although nonsignificant, was noted for diabetics (67 vs.
31%). The proportion of rapid vs. slow metabolisers was
not influenced by other patient characteristics (gender,
Evaluation of the fluctuations in haemodynamic parametersFig re 2
Evaluation of the fluctuations in haemodynamic 
parameters. Schematic representation of the method used 
to calculate the maximum increase and decrease of each 
measured parameter during the dialysis session.Page 4 of 11
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Table 1: Characteristics of the studied population. Characteristics of the cohort at the beginning of the study
Patient no. Sex Age (y) Underlying 
nephropathy
Comorbidities Medication Dry weight (kg) Dialyser 
surface 
area(m2)
Dialysis 
Duration (h)
Ischemic 
cardio-
myopathy
Diabetes 
mellitus
Beta-
blockers
Calcium 
antagonists
Alpha-
blockers
ACE-inhibitors 
or ARB
1 F 64 Nephroangiosclerosis N N Y Y N Y 57.00 1.8 3.0
2 F 56 Nephroangiosclerosis N N Y Y N Y 64.00 1.8 3.5
3 F 88 Nephroangiosclerosis N N Y N Y Y 64.00 1.8 3.0
4 M 59 Focal segmental 
glomerulosclerosis
N Y Y N N Y 80.0 2.2 3.5
5 F 75 Diabetic nephropathy N Y Y Y Y Y 48.50 1.8 3.5
6 M 74 Nephroangiosclerosis N N N N N N 71.00 1.8 4.0
7 M 68 IgA nephropathy Y N N N N Y 94.65 1.8 4.0
8 F 65 Diabetic nephropathy Y Y Y Y Y Y 47.00 1.8 3.5
9 F 66 Nephroangiosclerosis N N N Y Y N 49.00 1.8 3.5
10 M 77 Interstitial Nephritis N N N Y N Y 99.50 1.8 3.5
11 M 72 Nephroangiosclerosis Y N Y N N Y 92.00 1.8 3.0
12 F 48 IgA nephropathy N Y Y N N N 64.50 2.2 3.5
13 M 77 Nephroangiosclerosis Y N Y Y N N 89.40 1.8 3.0
14 M 81 Nephroangiosclerosis N N Y Y N N 79.65 1.8 3.5
15 M 59 Diabetic nephropathy Y Y Y N N Y 99.00 1.8 4.0
16 M 88 Nephroangiosclerosi N N Y N N N 65.15 1.8 4.0
18 M 64 Nephroangiosclerosis N Y Y Y Y N 97.00 1.8 3.5
17 F 74 Diabetic nephropathy N Y N Y N N 80.00 1.8 3.5
19 M 65 Focal segmental 
glomerulosclerosis
N N Y N N N 86.00 2.2 4.0
20 F 75 Diabetic nephropathy Y Y Y N N Y 68.50 1.8 3.0
21 M 81 Nephroangiosclerosis Y N Y N N Y 69.20 1.8 4.0
22 M 72 Diabetic nephropathy Y Y N N N Y 88.00 1.8 4.0
23 M 88 Nephroangiosclerosis Y Y N Y N Y 83.50 1.8 3.0
24 M 71 Nephroangiosclerosis Y Y Y N N Y 74.50 2.2 4.5
25 F 70 Nephroangiosclerosis N N Y Y N Y 48.20 1.8 3.0
M, male; F, female; Y, yes; N, no; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor antagonists
BMC Nephrology 2009, 10:7 http://www.biomedcentral.com/1471-2369/10/7weight) or haemodialysis parameters (dialyser effective
surface area and dialysis duration).
Dialysis efficiency
As also observed in previous studies, the use of citrate was
associated with a significant decrease in steady state pre-
dialysis BUN (-1.8 mmol/L; p < 0.05). There was a similar
albeit nonsignificant trend for post-dialysis BUN (- 0.4
mmol/L) and consequently for Kt/V (+0.02) (see Table 4
for details).
As stated above, phosphate removal was significantly
increased (comparing acetate with citrate: -0.13 mmol/L
in post-dialysis phosphate concentration; p < 0.001).
Coagulation parameters
Measurements of thrombin-antithrombin complexes
(TAT) and prothrombin fragments 1+2 (F1+2) indicated a
significant systemic activation of the coagulation cascade
during dialysis that was not influenced by the choice of
dialysate (see Table 6 for details).
Citrate tolerance
The need for intervention by the medical staff was the
same with the two dialysis schedules (see Table 4 for
details). The subjective tolerance for citrate and acetate
was also similar, with a trend favouring citrate (80% of the
patients reported no changes while 16% noted an
improvement and 4% a worsening with citrate instead of
acetate). Adverse events or significant side effects were not
reported.
Discussion
Haemodynamic consequences of dialysis fluids containing 
citrate instead of acetate
The use of citrate in dialysis fluids was associated with sig-
nificant haemodynamic changes during haemodialysis.
Specifically, we found a mean decrease in systolic and
Table 2: Haemodynamic consequences of using citric instead of acetic acid in dialysis fluids. 
Acetate (A) Citrate (C) Citrate (C+) MD (AC) MD (AC+) P(Avs.C) P(Avs.C+)
Systolic BP (mmHg) 132.8 ± 15.5 128.5 ± 14.1 130.7 ± 20.2 4.3 2.1 < 0.01 ns
Diastolic BP(mmHg) 69.5 ± 9.8 67.9 ± 9.1 68.7 ± 11.6 1.6 0.8 < 0.05 ns
Heart rate (beat/min) 67.6 ± 10.8 67.8 ± 12.3 68.3 ± 12.5 -0.2 -0.7 ns ns
Blood volume (%) 96.3 ± 2.8 96.6 ± 2.9 95.6 ± 3.1 -0.3 0.7 ns ns
Stroke volume (ml) 56.6 ± 16.1 61.5 ± 14.8 63.5 ± 13.1 -5.0 -6.9 ns ns
Peripheral resistence (dyne.sec.cm-5) 1633 ± 524 1581 ± 410 1407 ± 235 51 226 < 0.001 < 0.001
Blood pressure (BP) and pulse-wave analysis results based on the area under the curve using acetate dialysate (A) vs. citrate dialysate with (C+) or 
without (C) calcium supplementation.
ns, non significant, MD: mean difference
Systolic blood pressureFigure 3
Systolic blood pressure. Systolic blood pressure as a func-
tion of the haemodialysis time using, respectively, acetate (A) 
(empty diamonds), calcium uncorrected citrate (C) (black 
squares) and calcium supplemented citrate dialysate (C+) 
(black triangles).
Diastolic blood pressureFigure 4
Diastolic blood pressure. Diastolic blood pressure as a 
function of the haemodialysis time using, respectively, acetate 
(A) (empty diamonds), calcium uncorrected citrate (C) (black 
squares) and calcium supplemented citrate dialysate (C+) 
(black triangles).Page 6 of 11
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tively) mediated by a reduction in peripheral resistances (-
51 dyne.sec.cm-5) and incompletely compensated by a
nonsignificant increase in stroke volume (5.0 ml) (Table
2). The changes in peripheral resistances were independ-
ent of the effect of citrate on calcium balance, as con-
firmed by the use of a dialysate supplemented with the
amount of calcium necessary to compensate for its bind-
ing to citrate (0.25 mmol/L) (Table 2). Even if the citrate
modality was associated with both lower mean systolic
and diastolic BP and mean peripheral resistances, analysis
of the extremes of fluctuations of the latter parameter sug-
gested that citrate use improved systemic haemodynamic
stability. In fact, despite the contrasting behaviour of BP,
the maximum decrease and increase in peripheral resist-
ances was more pronounced with acetate use (maximum
decrease 974 vs. 485 and maximum increase 905 vs. 792
dyne.sec.cm-5) (Table 3).
Heart rateFigure 5
Heart rate. Heart rate as a function of the haemodialysis 
time using, respectively, acetate (A) (empty diamonds), cal-
cium uncorrected citrate (C) (black squares) and calcium 
supplemented citrate dialysate (C+) (black triangles).
Blood volumeFigure 6
Blood volume. Blood volume as a function of the haemodi-
alysis time using respectively acetate (A) (empty diamonds), 
calcium uncorrected citrate (C) (black squares) and calcium 
supplemented citrate dialysate (C+) (black triangles).
Stroke volumeFigure 7
Stroke volume. Stroke volume as a function of the haemo-
dialysis time using, respectively, acetate (A) (empty dia-
monds), calcium uncorrected citrate (C) (black squares) and 
calcium supplemented citrate dialysate (C+) (black triangles).
Peripheral resistanceFigur  8
Peripheral resistance. Peripheral resistance as a function 
of the haemodialysis time using, respectively, acetate (A) 
(empty diamonds), calcium uncorrected citrate (C) (black 
squares) and calcium supplemented citrate dialysate (C+) 
(black triangles).Page 7 of 11
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containing dialysate resulted in a more pronounced
reduction in blood pressure in the subgroup of patients
with an intradialytic hypertension (Figure 9).
Acid-base status and electrolyte changes
As expected, citrate dialysis was associated with an
increase in steady-state pre-dialysis bicarbonate. The con-
sequences of citrate on bicarbonataemia may be
explained by the incomplete conversion of citrate into
bicarbonate during the dialysis session, as confirmed by
the increased gap between total and ionised calcium (cal-
cium gap), reflecting the hepatic and muscular metabo-
lism of citrate that occurred in part after the end of the
dialysis session. Interestingly it was also observed that
peripheral perfusion and muscle mass are probably
related to the rate of intra-dialytic citrate removal. This
was established by classifying patients as rapid or slow
metabolisers according to their calcium gap (proportional
to unmetabolised citrate). Among the slow metabolisers,
the percentage of patients with a net ultrafiltration during
dialysis > 2L was significantly higher (64 vs. 8%) while a
similar, although nonsignificant trend was seen in diabet-
ics (67 vs. 31%) (see Table 6 for details). The accumula-
tion of citrate in these patients could in fact be explained
by a lower muscle mass or a less efficient muscle perfusion
related to vasoconstriction.
Since the dialysis sessions lasted no more than 4 hours
and the calcium gap did not correlate with dialysis dura-
tion, the amount of unmetabolised citrate resulting from
longer haemodialyses could not be determined in the
present study.
While there were no changes in the pre-dialysis ionised
calcium, post-dialysis values were significantly lower in
the group using the citrate dialysate (1.22 vs. 1.14
mnmol/L; -7%). As expected, patients treated with a dial-
ysis fluid containing 1.25 mmol calcium/L, were found to
have an asymptomatic post-dialysis hypocalcaemia. Sup-
plementation of the dialysate with 0.25 mmol calcium/L
completely corrected the difference in post-dialysis cal-
cium concentration between the acetate and citrate
modalities (see Table 5 for details). Post-dialysis hypocal-
caemia was always asymptomatic and patients spontane-
ously recovered in the interdialytic phase. Nevertheless,
patients treated with a dialysate in which the calcium con-
centration is 1.25 mmol/L require careful monitoring of
the serum calcium when converted to citrate-based dialy-
Table 3: Haemodynamic consequences of using citric instead of acetic acid in dialysis fluids II. 
Acetate (A) Citrate (C) Citrate (C+) P(Avs.C) P(Avs.C+)
Systolic BP (mmHg) max.decrease 19.2 ± 9.61 25.6 ± 10.98 23.4 ± 13.43 < 0.01 ns
max.increase 13.96 ± 8.28 9.07 ± 7.84 11.01 ± 8.32 < 0.05 ns
Diastolic BP (mmHg) max.decrease 10.60 ± 4.06 12.18 ± 5.13 10.68 ± 5.99 ns ns
max.increase 7.42 ± 5.56 7.33 ± 5.54 7.95 ± 5.03 ns ns
Blood volume # (%) max.decrease 6.05 ± 4.21 4.81 ± 3.51 6.47 ± 3.88 ns ns
max increase 0.99 ± 0.95 1.21 ± 1.26 0.44 ± 0.70 ns < 0.05
Heart rate # (beat/min) max.decrease 8.04 ± 5.99 7.79 ± 5.76 7.81 ± 6.92 ns ns
max increase 4.03 ± 3.21 3.27 ± 2.95 4.03 ± 4.28 ns ns
Stroke volume (ml) max.decrease 17.20 ± 9.78 19.62 ± 10.41 14.90 ± 16.65 ns ns
max.increase 28.14 ± 15.22 28.26 ± 32.24 23.04 ± 23.97 ns ns
Peripheral resistence max.decrease 973.60 ± 571.25 485.30 ± 267.25 410.37 ± 330.91 < 0.001 < 0.001
(dyne.sec.cm-5) max.increase 904.73 ± 376.18 791.69 ± 464.17 741.30 ± 528.75 ns ns
Blood volume, blood pressure (BP), heart rate, stroke volume and peripheral resistance fluctuations during dialysis using acetate dialysate (A) vs. 
citrate dialysate with (C+) or without (C) calcium supplementation.
Systolic blood pressure in hypertensive patientsFigure 9
Systolic blood pressure in hypertensive patients. 
Systolic blood pressure as a function of the haemodialysis 
time using, respectively, acetate (A) (empty diamonds) and 
calcium uncorrected citrate (C) (black squares) dialysate in 
the subgroup of patients with an intradialytic systolic blood 
pressure increase during dialysis of more than 15 mmHg and 
at least one value of more than 150 mmHg (n = 8).Page 8 of 11
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calcium in the dialysate.
Dialysis efficiency
As shown in previous studies, the use of citrate was asso-
ciated with an increased removal of phosphate and urea.
In contrast to Ahmad's study [22], in which a significant
difference was reported, we observed only a trend favour-
ing an increase in Kt/V; the absence of significance/statis-
tical power may have been due to the use of single-use
dialysers (see Table 4 for details).
In addition, since a correction of acidosis improves catab-
olism [27], the lower pre-dialysis BUN might be explained
by a reduced generation of urea, resulting from the
improved acid-base status obtained using citrate.
Coagulation parameters
Thrombin-antithrombin complexes and prothrombin
fragments 1+2 are very sensitive markers of systemic coag-
ulation activation during haemodialysis [9]. The absence
of significant changes in their concentrations between the
two dialysis schedules leads to the conclusion that sys-
temic coagulation activation was not influenced by dia-
lysate composition. This confirms that the effect of citrate
is limited to the dialyser and that the inhibition of the
coagulation cascade taking place in the extracorporeal cir-
cuit is incomplete with either method. Since in the present
study the extracorporeal circuit was not evaluated for clot-
ting and the heparin dose was not down-titrated, the clin-
ical relevance of the intradialyser coagulation inhibition
related to the use of citrate cannot be conclusively stated.
Table 4: Acid-base status, electrolyte changes and dialysis efficiency. 
Acetate (A) Citrate (C) P(A vs.C)
Ultrafiltered volume (L) 1.88 ± 0.98 1.85 ± 0.96 ns
Dialyses with need of staff intervention (%) 4 3 ns
Bicarbonate (mmol/l) pre-dialysis 20.6 ± 2.5 21.5 ± 2.8 < 0.01
post-dialysis 25.8 ± 1.9 24.3 ± 2.4 < 0.001
pH, whole blood pre-dialysis 7.33 ± 0.04 7.33 ± 0.04 ns
post-dialysis 7.43 ± 0.03 7.41 ± 0.03 < 0.001
Phosphate (mmol/l) pre-dialysis 1.58 ± 0.39 1.54 ± 0.37 ns
post-dialysis 0.62 ± 0.15 0.49 ± 0.13 < 0.001
Potassium, serum (mmol/l) pre-dialysis 4.74 ± 0.72 4.78 ± 0.66 ns
post-dialysis 3.68 ± 0.26 3.70 ± 0.20 ns
Creatinine (umol/l) pre-dialysis 494 ± 147 480 ± 166 ns
post-dialysis 189 ± 60 182 ± 68 ns
BUN mmol/l pre-dialysis 21.7 ± 6.5 19.8 ± 6.6 < 0.05
post-dialysis 6.0 ± 2.8 5.6 ± 2.4 ns
Kt/V 1.52 ± 0.37 1.53 ± 0.31 ns
Ultrafiltered volume, % of dialyses requiring staff intervention, bicarbonate, phosphate, potassium, pH in whole blood, creatinine, BUN at the 
beginning and at the end of the dialysis sessions and Kt/V using acetate dialysate (A) vs. citrate (C) dialysate without calcium supplementation.
Table 5: Calcium balance. 
Acetate (A) Citrate (C) Citrate (C+) P(Avs.C) P(Avs.C+)
Calcium, serum, ionised (mmol/l) pre-dialysis 1.19 ± 0.09 1.20 ± 0.07 1.23 ± 0.08 ns < 0.01
post-dialysis 1.22 ± 0.10 1.14 ± 0.10 1.31 ± 0.10 < 0.001 < 0.001
Patients with dialysate calcium concentration of 
1.25 mmol/l
Calcium, serum, ionised (mmol/l) pre-dialysis 1.14 ± 0.04 1.16 ± 0.04 1.16 ± 0.06 ns ns
post-dialysis 1.09 ± 0.03 0.99 ± 0.02 1.13 ± 0.07 < 0.01 ns
Patients with dialysate calcium concentration of 
1.50 mmol/l
Calcium, serum, ionised (mmol/l) pre-dialysis 1.19 ± 0.10 1.21 ± 0.08 1.24 ± 0.08 ns < 0.05
post-dialysis 1.27 ± 0.06 1.19 ± 0.05 1.34 ± 0.05 < 0.001 < 0.001
Serum ionised calcium at the beginning and at the end of the dialysis sessions using acetate dialysate (A) vs. citrate dialysate with (C+) or without 
(C) calcium supplementation.Page 9 of 11
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Intervention by the medical staff was the same in the cit-
rate group as in the acetate group. The responses to a
patient questionnaire assessing subjective tolerance of the
dialysis sessions indicated a nonsignificant trend in favour
of citrate.
Conclusion
The use of citrate rather than acetate as a dialysate in bicar-
bonate haemodialysis decreases peripheral resistances
and slightly reduces systolic and diastolic blood pressures.
Nonetheless, both the analysis of maximum fluctuations
in peripheral resistances during dialysis and data describ-
ing subjective tolerance suggest a trend towards improved
haemodynamic stability for patients on the citrate sched-
ule. Interestingly, patients developing intradialytic hyper-
tension experienced a larger reduction in blood pressure.
Even with single-use dialysers, citrate resulted in better
urea and phosphate removal, probably by preventing clot-
ting of the dialyser fibres. To maintain the same intradia-
lytic calcium balance following the switch to citrate, the
calcium concentration of the dialysate should be
increased of about 0.25 mmol/L. However, considering
that steady-state pre-dialysis calcium was not significantly
modified by the use of citrate, the need for calcium sup-
plementation of the dialysate, particularly in patients
treated with a 1.25 mmol calcium/L regimen, should be
individually determined. In the citrate modality, a sys-
temic effect on the coagulation cascade, as evaluated by
specific markers, was not detected. This was probably
associated with reduced intra-dialyser coagulation activa-
tion. Therefore, even if the use of citrate dialysate is rec-
ommended, in order to reduce the need for
anticoagulants in patients at risk of bleeding, this aspect
needs further investigation.
The positive impact of the citrate dialysate on dialyser effi-
ciency, on acid-base status and the haemodynamic pat-
tern as well as the subjective tolerance together suggest
that the substitution of citrate for acetate in dialysis fluids
improves haemodialysis in selected patients.
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